---
title: Analysis of Heart Rate Variability After a Physical Exercise Session
nct_id: NCT05798975
overall_status: COMPLETED
phase: NA
sponsor: Instituto de Cardiologia do Rio Grande do Sul
study_type: INTERVENTIONAL
primary_condition: Hypertension
countries: Brazil
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05798975.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05798975"
ct_last_update_post_date: 2025-05-14
last_seen_at: "2026-05-12T07:14:44.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Analysis of Heart Rate Variability After a Physical Exercise Session

**Official Title:** Analysis of Heart Rate Variability After One Session of Aerobic or Resistance Physical Exercise in Controlled Hypertensive Individuals: Randomized Clinical Trial

**NCT ID:** [NCT05798975](https://clinicaltrials.gov/study/NCT05798975)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 36
- **Lead Sponsor:** Instituto de Cardiologia do Rio Grande do Sul
- **Conditions:** Hypertension
- **Start Date:** 2022-04-01
- **Completion Date:** 2024-11-30
- **CT.gov Last Update:** 2025-05-14

## Brief Summary

Systemic arterial hypertension (SAH) is a multifactorial clinical condition, characterized by sustained elevation of blood pressure levels, contributing to 50% of deaths from cardiovascular disease. The Autonomic Nervous System (ANS) plays a fundamental role in the regulation of Blood Pressure (BP) and is closely associated with Heart Rate (HR). HR changes are called Heart Rate Variability (HRV). In individuals with SAH, HRV indices are reduced compared to normotensive individuals, showing changes in autonomic modulation, thus increasing the risk for cardiovascular events. The objective of this study will be to analyze the Heart Rate Variability in individuals with controlled SAH after a session of aerobic (EA) or resistance (RE) physical exercise.

## Detailed Description

Controlled hypertensive individuals aged between 30 and 59 years will be selected, for convenience, who use the services of the Instituto de Cardiologia do Rio Grande do Sul. Volunteers will be randomly assigned to an EA session (40 minutes on cycle ergometer, 60% of heart rate reserve) or RE (2 exercises for lower limbs and 2 for upper limbs with 4 sets of 12 repetitions at 60% 1-RM) or control group without exercise. HRV data will be collected by ECG (Wincardio USB - Version 11.1.0.0, MICROMED Biotecnologia Ltda, Brasília - DF - Brazil) during 10 minutes before the exercise session, 10 minutes after the exercise session, 1h and 2h post-session . It is expected to estimate results that may demonstrate clarifications about the impact of a physical exercise session on HRV in controlled hypertensive individuals.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 59 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Controlled Systemic Alterial Hypertension

Exclusion Criteria:

* Diabetes mellitus;
* heart failure;
* coronary artery disease;
* chronic renal failure;
* body mass index (BMI) ≥ 35 kg/m2;
* smokers;
* individuals with injuries to the upper and lower limbs that make the exercise protocol impossible;
* not using antihypertensive medication and using beta-blocker and/or alpha-blocker medication.
```

## Arms

- **Aerobic Physical Exercise** (EXPERIMENTAL) — Cycle ergometer exercise
- **Resistance Physical Exercise** (EXPERIMENTAL) — Exercise with weights
- **Control** (NO_INTERVENTION) — No exercise. Rest

## Interventions

- **Aerobic Exercise. 1 session of acute exercise** (OTHER) — 40 minutes on cycle ergometer, 60% of heart rate reserve
- **Resistance Exercise. 1 session of acute exercise** (OTHER) — 2 exercises for lower limbs and 2 for upper limbs with 4 sets of 12 repetitions at 60% 1-RM. 40 minutes
- **no exercise** (OTHER) — Rest

## Primary Outcomes

- **Heart Rate Variability.** _(time frame: 4 hours)_ — Analysis of heart rate variability with Wincardio Digital ECG.

## Locations (1)

- Diego Silveira da Silva, Porto Alegre, Rio Grande do Sul, Brazil

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.diego silveira da silva|porto alegre|rio grande do sul|brazil` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05798975.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05798975*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*